In order to better guide the safe and rational use of drugs in clinical practice, our company, in accordance with the requirements of the "Special Provisions on the Registration Management of Traditional Chinese Medicine" announced by the National Medical Products Administration (No. 20, 2023), has proactively conducted post-marketing research on the safety information of Qizao Granules, revised the contents of "Adverse Reactions", "Contraindications" and "Precautions" in the instructions and la